171 related articles for article (PubMed ID: 31404445)
1. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.
Al-Kawaaz M; Sanchez T; Kluk MJ
J Hematop; 2019 Jun; 12(2):57-65. PubMed ID: 31404445
[TBL] [Abstract][Full Text] [Related]
2. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
3. A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification.
Jesionek-Kupnicka D; Braun M; Robak T; Kuncman W; Kordek R
Adv Clin Exp Med; 2019 Oct; 28(10):1359-1365. PubMed ID: 31518494
[TBL] [Abstract][Full Text] [Related]
4. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.
Bischin AM; Dorer R; Aboulafia DM
Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Pathological Features of Double-Hit and Triple-Hit High-Grade B-Cell Lymphomas: A Retrospective Study from Three Portuguese Tertiary Centers.
Almeida R; Abrantes C; Gigliano D; Oliveira RC; Teixeira P; Viegas M; Rodrigues Â; Julião MJ
Int J Hematol Oncol Stem Cell Res; 2022 Apr; 16(2):94-102. PubMed ID: 36304730
[No Abstract] [Full Text] [Related]
6. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Graef CM; Gödel P; Falderbaum P; Balke-Want H; Simon F; Sieg N; Naendrup JH; Neumann MA; Gillessen S; Bröckelmann PJ; Eichenauer DA; Borchmann P; von Tresckow B; Heger JM
Eur J Haematol; 2022 May; 108(5):403-412. PubMed ID: 35090068
[TBL] [Abstract][Full Text] [Related]
7. High-Grade B-Cell Lymphoma (HGBL) with
Tsai CC; Su YC; Bamodu OA; Chen BJ; Tsai WC; Cheng WH; Lee CH; Hsieh SM; Liu ML; Fang CL; Lin HT; Chen CL; Yeh CT; Lee WH; Ho CL; Lai SW; Tzeng HE; Hsieh YY; Chang CL; Zheng YM; Liu HW; Yen Y; Whang-Peng J; Chao TY
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807449
[TBL] [Abstract][Full Text] [Related]
8. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
9. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G
Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392
[TBL] [Abstract][Full Text] [Related]
10. Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge AV; Duetz C; Bruins WSC; Korst CLBM; Rentenaar R; Cosovic M; Eken M; Twickler I; Nijland M; van der Poel MWM; de Heer K; Klerk CPW; Strobbe L; Oosterveld M; Boersma R; Koene HR; Roemer MGM; van Werkhoven E; Chamuleau MED; Mutis T
Blood Adv; 2024 Mar; 8(5):1094-1104. PubMed ID: 38191686
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas.
Paik JH; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
BMC Cancer; 2014 Dec; 14():911. PubMed ID: 25472725
[TBL] [Abstract][Full Text] [Related]
12. Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.
Tanaka Y; Momose S; Tabayashi T; Sawada K; Yamashita T; Higashi M; Sagawa M; Tokuhira M; Rosenwald A; Kizaki M; Tamaru JI
Cancer Sci; 2020 Feb; 111(2):749-759. PubMed ID: 31849147
[TBL] [Abstract][Full Text] [Related]
13. High-grade B-Cell lymphoma with
Rogers TS; Gardner JA; Devitt KA
Autops Case Rep; 2019; 9(3):e2019090. PubMed ID: 31440479
[TBL] [Abstract][Full Text] [Related]
14. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
[TBL] [Abstract][Full Text] [Related]
15. Advances in pathological understanding of high-grade B cell lymphomas.
Li S; Lin P; Medeiros LJ
Expert Rev Hematol; 2018 Aug; 11(8):637-648. PubMed ID: 29989509
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomic Profiling of High-Grade B-Cell Lymphoma With 11q Aberrations and Burkitt Lymphoma Reveals Lymphoid Enhancer Binding Factor 1 as a Novel Biomarker.
Hurwitz SN; Lockhart B; Önder Ö; Wu R; Sethi S; Aypar U; Siebert R; Dogan A; Pillai V; Elenitoba-Johnson KSJ; Lim MS
Mod Pathol; 2023 Jul; 36(7):100170. PubMed ID: 36997001
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.
Middle S; Coupland SE; Taktak A; Kidgell V; Slupsky JR; Pettitt AR; Till KJ
Exp Hematol Oncol; 2015; 4():10. PubMed ID: 25938000
[TBL] [Abstract][Full Text] [Related]
18. De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with
Uchida A; Isobe Y; Uemura Y; Nishio Y; Sakai H; Kato M; Otsubo K; Hoshikawa M; Takagi M; Miura I
BMC Clin Pathol; 2017; 17():21. PubMed ID: 29151814
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma.
Koresawa R; Yamazaki K; Oka D; Fujiwara H; Nishimura H; Akiyama T; Hamasaki S; Wada H; Sugihara T; Sadahira Y
Br J Haematol; 2016 Jul; 174(2):264-74. PubMed ID: 27061580
[TBL] [Abstract][Full Text] [Related]
20. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
Ott G
Br J Haematol; 2017 Sep; 178(6):871-887. PubMed ID: 28748558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
